Cargando…
Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy
BACKGROUND AND PURPOSE: Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated. METHODS: Eighty-five patients received perampane...
Autores principales: | Youn, Song Ee, Kim, Se Hee, Ko, Ara, Lee, Sun Ho, Lee, Young Mock, Kang, Hoon-Chul, Lee, Joon Soo, Kim, Heung Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Neurological Association
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031997/ https://www.ncbi.nlm.nih.gov/pubmed/29971974 http://dx.doi.org/10.3988/jcn.2018.14.3.296 |
Ejemplares similares
-
Long-term efficacy and safety of adjunctive perampanel in pediatric patients aged 4–19 years with epilepsy: a real-world study
por: Youn, Song Ee, et al.
Publicado: (2023) -
Efficient strategy for the molecular diagnosis of intractable early-onset epilepsy using targeted gene sequencing
por: Rim, John Hoon, et al.
Publicado: (2018) -
Epilepsy Surgery in Pediatric Intractable Epilepsy with Destructive Encephalopathy
por: Park, So Young, et al.
Publicado: (2013) -
Adjunctive perampanel for glioma-associated epilepsy()
por: Dunn-Pirio, Anastasie M., et al.
Publicado: (2018) -
Effective application of corpus callosotomy in pediatric intractable epilepsy patients with mitochondrial dysfunction
por: Na, Ji-Hoon, et al.
Publicado: (2022)